Genome editing is an umbrella term for a range of tools that enable precise changes to the genome of an organism. Applied worldwide by researchers in academia, governmental research institutions and industry, these innovations represent a promising next step in research towards beneficial uses in medicine, agriculture and the bio-economy aimed at addressing some of society’s grand challenges.
At EuropaBio, genome editing is a key topic dealt with by our New Technologies Working Group. For information on the group please contact Christopher Gallasch below.
Over 20 EU business associations call for innovation-friendly rules on mutagenesis
An open letter jointly calls upon member states and the EU Commission to initiate a legislative change to ensure that targeted genetic variation in organisms can help Europe to achieve important sustainable development goals.
Court ruling could lock out the benefits of genome editing from Europe
Responding to today’s Court of Justice of the EU ruling on organisms obtained by mutagenesis (Case C-528/16), EuropaBio’s Secretary General John Brennan highlighted industry’s concerns about the judgement.